关于同意申万宏源证券有限公司为华夏上证科创板生物医药交易型开放式指数证券投资基金提供主做市服务的公告

上交所2025-07-10

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！上证公告（基金）【2025】1034号为促进华夏上证科创板生物医药交易型开放式指数证券投资基金（以下简称科创药，基金代码:588130）的市场流动性和平稳运行，根据《上海证券交易所基金自律监管规则适用指引第2号——上市基金做市业务》等相关规定，本所同意申万宏源证券有限公司自2025年07月10日起为科创药提供主做市...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2550667523?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-10 09:11","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2550667523","market":"us","top_or_hot":-1,"title":"关于同意申万宏源证券有限公司为华夏上证科创板生物医药交易型开放式指数证券投资基金提供主做市服务的公告","media":"上交所","content":"<div>\n<p>炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 上证公告（基金）【2025】1034号    为促进华夏上证科创板生物医药交易型开放式指数证券投资基金（以下简称科创药，基金代码:588130）的市场流动性和平稳运行，根据《上海证券交易所基金自律监管规则适用指引第2号——上市基金做市业务》等相关规定，本所同意申万宏源证券有限公司自2025年07月10日起为科创药提供主做市...</p>\n\n<a href=\"https://finance.sina.com.cn/roll/2025-07-10/doc-infexwev1981078.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>关于同意申万宏源证券有限公司为华夏上证科创板生物医药交易型开放式指数证券投资基金提供主做市服务的公告</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n关于同意申万宏源证券有限公司为华夏上证科创板生物医药交易型开放式指数证券投资基金提供主做市服务的公告\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-10 09:11 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/roll/2025-07-10/doc-infexwev1981078.shtml><strong>上交所</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 上证公告（基金）【2025】1034号    为促进华夏上证科创板生物医药交易型开放式指数证券投资基金（以下简称科创药，基金代码:588130）的市场流动性和平稳运行，根据《上海证券交易所基金自律监管规则适用指引第2号——上市基金做市业务》等相关规定，本所同意申万宏源证券有限公司自2025年07月10日起为科创药提供主做市...</p>\n\n<a href=\"https://finance.sina.com.cn/roll/2025-07-10/doc-infexwev1981078.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1147","symbol_name":"投资银行业与经纪业","start_time":0,"source_url":"https://finance.sina.com.cn/roll/2025-07-10/doc-infexwev1981078.shtml","article_id":"2550667523","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2550667523","pubTimestamp":1752109860,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 上证公告（基金）【2025】1034号    为促进华夏上证科创板生物医药交易型开放式指数证券投资基金（以下简称科创药，基金代码:588130）的市场流动性和平稳运行，根据《上海证券交易所基金自律监管规则适用指引第2号——上市基金做市业务》等相关规定，本所同意申万宏源证券有限公司自2025年07月10日起为科创药提供主做市服务。    特此公告。    上海证券交易所    2025年07月10日                    \n\n\n海量资讯、精准解读，尽在新浪财经APP","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159982":"中证500","161027":"证券","161726":"生物医药","399300":"沪深300","399441":"生物医药","BK1147":"投资银行业与经纪业","BK0276":"资本市场","BK0012":"证金概念","000001.SH":"上证指数","BK1564":"中资券商股","000166":"申万宏源","06806":"申万宏源","BK0028":"国家队","BK0183":"MSCI概念","BK0188":"融资融券"},"translate_title":"Announcement on approving Shenwan Hongyuan Securities Co., Ltd. to provide main market-making services for ChinaAMC SSE Science and Technology Innovation Board Biomedical Trading Open-end Index Securities Investment Fund","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159982":1,"161027":1,"161726":1,"399300":1,"399441":1,"000166":1,"000001.SH":1,"06806":1},"content_text":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 上证公告（基金）【2025】1034号    为促进华夏上证科创板生物医药交易型开放式指数证券投资基金（以下简称科创药，基金代码:588130）的市场流动性和平稳运行，根据《上海证券交易所基金自律监管规则适用指引第2号——上市基金做市业务》等相关规定，本所同意申万宏源证券有限公司自2025年07月10日起为科创药提供主做市服务。    特此公告。    上海证券交易所    2025年07月10日                    \n\n\n海量资讯、精准解读，尽在新浪财经APP","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2550667523","isCrawlerRequest":true}